07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Paracelsian board of directors update

Paracelsian Inc. (PRLN), Ithaca, N.Y.   Business: Cancer, Diagnostics/Imaging   Appointed: Lee Henderson, Ph.D., chairman and CEO of Viral Therapeutics Inc. ; Stephen Ip, Ph.D., EVP and COO of American Biogenetic Sciences Inc. (MABXA, Coppiague,...
07:00 , May 13, 2002 |  BC Week In Review  |  Company News

American Biogenetic management update

American Biogenetic Sciences Inc. (MABAA), Copiague, N.Y.   Business: Cardiovascular, Neurological   Promoted: James McLinden to president, COO and a director, while remaining CSO; he replaces Josef Schoell, who will remain a director  ...
08:00 , Dec 3, 2001 |  BC Week In Review  |  Company News

American Biogenetic, Ministry of Health of the Russian Federation deal

MABA obtained from the Ministry the rights to produce and distribute vaccines developed in Russia for anthrax, smallpox, botulism and other human diseases, as well as certain livestock vaccines in Europe, North and South America...
08:00 , Nov 19, 2001 |  BC Week In Review  |  Company News

American Biogenetic, Abbott deal

ABT discontinued its licensing agreement for MABA's ABS-103 valproic acid analog to treat epilepsy and bipolar mania and prevent migraine. MABA said it is seeking another partner for the preclinical product. American Biogenetic Sciences Inc....
07:00 , Oct 1, 2001 |  BC Week In Review  |  Clinical News

ABS-103 valproic acid analog regulatory update

MABA received U.S. Patent No. 6,268,396 covering the use of the valproic acid analog 2-n-propyl-4-hexynoic acid to prevent and treat migraine and affective illness (unipolar or bipolar disorders and acute mania). ABT is the exclusive...
07:00 , Jul 9, 2001 |  BC Week In Review  |  Company News

American Biogenetic, PanBio Ltd. deal

MABA sold its Stellar Bio Systems Inc. subsidiary (Columbia, Md.), which produces research products, to PanBio for a $1.2 million upfront cash payment and up to $540,000 in additional payments over three years based on...
07:00 , Apr 9, 2001 |  BC Week In Review  |  Company News

American Biogenetic, Biosite Diagnostics Inc. deal

BSTE will evaluate the use of MABA's Thrombus Precursor Protein ( TpP ) diagnostic marker and antibodies for use with BSTE's Triage Meter point-of-care testing platform. If BSTE decides to market products containing the MABA...
07:00 , Apr 3, 2001 |  BC Extra  |  Company News

American Biogenetic and Biosite in assay deal

BSTE will evaluate the use of MABA's Thrombus Precursor Protein ( TpP ) diagnostic marker and antibodies for use with BSTE's Triage Meter point-of-care testing platform. If it decides to market products containing the American...
08:00 , Feb 20, 2001 |  BC Week In Review  |  Clinical News

Monoclonal antibody to treat fibrin-containing tumors regulatory update

MABA received U.S. Patent No. 6,187,593 covering methods for using its MH-1 monoclonal antibody in conjunction with a cytotoxic reagent to treat malignant and benign tumors containing fibrin. American Biogenetic Sciences Inc. (MABA), Copiague, N.Y....
08:00 , Jan 16, 2001 |  BC Week In Review  |  Company News

American Biogenetic board of directors update

(Management, below) American Biogenetic Sciences Inc. (MABA), Copiague, N.Y.   Business: Diagnostics/Imaging   Appointed: Joseph Danis, an industry consultant  ...